Determining optimal combination regimens for patients with multiple myeloma.
Autor: | Aghaee M; Laboratory for Systems Medicine, College of Medicine, University of Florida, Gainesville, FL, USA., Ledzewicz U; Institute of Mathematics, Lodz University of Technology, Lodz, Poland; Dept. of Mathematics and Statistics, Southern Illinois University Edwardsville, Edwardsville, IL, USA., Robbins M; io904 LLC, Jacksonville Beach, FL, USA., Bezman N; Oncology Research and Development, Pfizer, La Jolla, California, USA., Jay Cho H; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Moore H; Laboratory for Systems Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. Electronic address: helen.moore@medicine.ufl.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2023 Aug 01; Vol. 187, pp. 106492. Date of Electronic Publication: 2023 Jun 09. |
DOI: | 10.1016/j.ejps.2023.106492 |
Abstrakt: | While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high-risk disease. In this work, we use a mathematical modeling approach to determine combination therapy regimens that maximize healthy lifespan for patients with multiple myeloma. We start with a mathematical model for the underlying disease and immune dynamics, which was presented and analyzed previously. We add the effects of three therapies to the model: pomalidomide, dexamethasone, and elotuzumab. We consider multiple approaches to optimizing combinations of these therapies. We find that optimal control combined with approximation outperforms other methods, in that it can quickly produce a combination regimen that is clinically-feasible and near-optimal. Implications of this work can be used to optimize doses and advance the scheduling of drugs. (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |